Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.50 |
| ▸ | CES1 | P23141 | 1/20 | 0.50 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.47 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.47 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3049902 | 0.81 | TLR7 (0.53) | CES2CES1TRPV1POLBTLR7 | |
| SCHEMBL5736589 | 0.81 | TRPV1 (0.42) | TRPV1MEN1NPC1MAPTRAB9A | |
| SCHEMBL26163219 | 0.74 | CES2 (0.57) | CES2CES1TRPV1NR4A1NR4A2 | |
| SCHEMBL2743436 | 0.74 | CES2 (0.61) | CES2CES1TRPV1NPC1RAB9A | |
| SCHEMBL3655196 | 0.74 | CES2 (0.61) | CES2CES1TRPV1NR4A1NR4A2 | |
| SCHEMBL31512899 | 0.73 | TRPV1 (0.50) | CES2CES1TRPV1POLBTLR7 | |
| SCHEMBL11029480 | 0.73 | KMT2A (0.51) | POLBMEN1NPC1MAPTRAB9A | |
| SCHEMBL72091 | 0.73 | CES2 (0.67) | CES2CES1TRPV1MAOBNR4A1 | |
| SCHEMBL16973935 | 0.73 | CES2 (0.55) | CES2CES1TRPV1MAOBNR4A1 | |
| SCHEMBL12251427 | 0.73 | MLYCD (0.71) | CES2CES1TRPV1NPC1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056505-A1 | Substituted Pyrazalones | BIOGEN IDEC MA INC. | 2010-03-04 | — | — | US | disclosed |
| EP-1971594-A2 | SUBSTITUTED PYRAZALONES | Biogen Idec MA Inc. (US) | 2008-09-24 | — | — | EP | disclosed |
| WO-2007059359-A2 | SUBSTITUTED PYRAZALONES | BIOGEN IDEC MA INC. (US) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056505-A1 | Substituted Pyrazalones | ACVR1, ACVRL1, TGFBR1 | CES2 4699/4885CES1 1648/4885TRPV1 2375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.